[Targeting delivery of liposomal adriamycin by intra-lymphatic infusion].
OBJECTIVE
To assess the feasibility of delivering liposomal adriamycin (lipo-ADM) to the regional lymph nodes via intralymphatic infusion in a rabbits model.


METHODS
The plasma and tissue ADM levels were measured by high performance liquid chromatography (HPLC) at 0.5 hour, 1 hour, 6 hours, 12 hours, 1 day, 7 days, 14 days, 28 days.


RESULTS
The maximum ADM level (Cmax) in the lymph nodes of lipo-ADM was 91.23 micrograms/g, which was 2 times higher than that of the free-ADM group. The area under the ADM concentrations-time curve (AUC) of the regional lymph nodes of lipo-ADM and free-ADM was 138.34 micrograms/day x g-1, 31.86 micrograms/day x g-1 respectively (P < 0.01). The pathological features showed that the lipo-ADM group had more microabscess, necrosis and fibrosis in the lymph nodes than those of the free-ADM group. The histological changes of heart were absent or slight in the lipo-ADM group.


CONCLUSIONS
lipo-ADM has a high affinity for lymphatic tissue. Intralymphatic infusion of lipo-ADM may be useful for the treatment of lymphnode metastasis in ovarian cancer.
Feng
B
B
Chinese Academy of Medical Sciences, Peking Union Medical College, Peking Union Hospital, Beijing.
Lang
J
J
Li
D
D
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004337:Drug Carriers; D005260:Female; D007272:Injections, Intralymphatic; D008081:Liposomes; D008198:Lymph Nodes / Q000378:metabolism; D008207:Lymphatic Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin